UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial

Multiple sclerosis, 2022-05, Vol.28 (6), p.925-932

2022

Volltextzugriff (PDF)

B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets

Therapeutic Advances in Neurological Disorders, 2018-01, Vol.11, p.1756286418761697-1756286418761697

2018

Volltextzugriff (PDF)

The Protein Network of HIV Budding

Cell, 2003-09, Vol.114 (6), p.701-713

2003

Volltextzugriff (PDF)

Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1

Molecular cancer therapeutics, 2011-12, Vol.10 (12), p.2267-2275

2011

Volltextzugriff (PDF)

Novel Mps1 kinase inhibitors: From purine to pyrrolopyrimidine and quinazoline leads

Bioorganic & medicinal chemistry letters, 2013-12, Vol.23 (24), p.6829-6833

2013

Volltextzugriff (PDF)

Marine Natural Product Libraries for High-Throughput Screening and Rapid Drug Discovery

Journal of natural products (Washington, D.C.), 2008-06, Vol.71 (6), p.1095-1098

2008

Volltextzugriff (PDF)

Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial

Rheumatology and therapy., 2023-12, Vol.10 (6), p.1795-1808

2023

Volltextzugriff (PDF)

Discovery of (2S)‑1-[4-(2-{6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]‑9H‑purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a Purine-Based Hsp90 Inhibitor

Journal of medicinal chemistry, 2012-09, Vol.55 (17), p.7480-7501

2012

Volltextzugriff (PDF)

Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors

Bioorganic & medicinal chemistry letters, 2012-07, Vol.22 (13), p.4377-4385

2012

Volltextzugriff (PDF)

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder

Neurology : neuroimmunology & neuroinflammation, 2021-05, Vol.8 (3)

2021

Volltextzugriff (PDF)

B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity

Annals of clinical and translational neurology, 2024-10, Vol.11 (10), p.2792-2798

2024

Volltextzugriff (PDF)

2-Anilino-4-aryl-1,3-thiazole inhibitors of valosin-containing protein (VCP or p97)

Bioorganic & medicinal chemistry letters, 2010-03, Vol.20 (5), p.1677-1679

2010

Volltextzugriff (PDF)

Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism

Annals of clinical and translational neurology, 2023-12, Vol.10 (12), p.2413-2420

2023

Volltextzugriff (PDF)

Oxindole derivatives as inhibitors of TAK1 kinase

Bioorganic & medicinal chemistry letters, 2011-03, Vol.21 (6), p.1724-1727

2011

Volltextzugriff (PDF)

The Locus Control Region Is Necessary for Gene Expression in the Human β-Globin Locus but Not the Maintenance of an Open Chromatin Structure in Erythroid Cells

Molecular and Cellular Biology, 1998-10, Vol.18 (10), p.5992-6000

1998

Volltextzugriff (PDF)

Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis

Clinical pharmacokinetics, 2022-03, Vol.61 (3), p.387-400

2022

Volltextzugriff (PDF)

Matching-adjusted Indirect Comparison of Current Treatments for NMOSD and Evaluation of Long-term Effectiveness (P10-14.006)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Safety and Efficacy of Inebilizumab in AQP4+ NMOSD Participants with History of Immunosuppression Treatment Prior to N-MOmentum Study (P13-5.003)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Genomic Targeting of Methylated DNA: Influence of Methylation on Transcription, Replication, Chromatin Structure, and Histone Acetylation

Molecular and Cellular Biology, 2000-12, Vol.20 (24), p.9103-9112

2000

Volltextzugriff (PDF)

Long-term Comparative Efficacy of Inebilizumab in the AQP4+ Subpopulation from N-MOmentum Open-label Period Versus Azathioprine and Immunosuppressants and Versus Placebo in Patients with NMOSD (S32.001)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Pharmacodynamic modeling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders (1872)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Replication Initiation Patterns in the β-Globin Loci of Totipotent and Differentiated Murine Cells: Evidence for Multiple Initiation Regions

Molecular and Cellular Biology, 2002-01, Vol.22 (2), p.442-452

2002

Volltextzugriff (PDF)

Pharmacodynamic modelling and exposure–response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders

British journal of clinical pharmacology, 2022-08, Vol.88 (8), p.3803-3812

2022

Volltextzugriff (PDF)

WED-152 Design and study population of MITIGATE: the first multinational randomized controlled clinical trial in IgG4 related disease, evaluating the efficacy and safety of the CD19 B cell depleting agent inebilizumab

Journal of hepatology, 2024-06, Vol.80, p.S710-S710

2024

Volltextzugriff (PDF)

Long-Distance Control of Origin Choice and Replication Timing in the Human β-Globin Locus Are Independent of the Locus Control Region

Molecular and Cellular Biology, 2000-08, Vol.20 (15), p.5581-5591

2000

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(48)
Dissertationen
(1)

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Humans
(22)
Animals
(12)
Clinical Neurology
(10)
Neurosciences & Neurology
(10)
Neuromyelitis Optica - Drug Therapy
(9)
Pharmacology & Pharmacy
(8)
Adult
(7)
Cell Biology
(7)
Mice
(7)
Monoclonal Antibodies
(7)
Aquaporin 4
(6)
Biochemistry & Molecular Biology
(6)
Chemistry, Medicinal
(6)
Inebilizumab
(6)
Neuromyelitis Optica Spectrum Disorder
(6)
Neurosciences
(6)
Cell Line
(5)
Globins - Genetics
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial

B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets

The Protein Network of HIV Budding

Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1

Novel Mps1 kinase inhibitors: From purine to pyrrolopyrimidine and quinazoline leads

Marine Natural Product Libraries for High-Throughput Screening and Rapid Drug Discovery

Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial

Discovery of (2S)‑1-[4-(2-{6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]‑9H‑purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a Purine-Based Hsp90 Inhibitor

Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder

B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity

2-Anilino-4-aryl-1,3-thiazole inhibitors of valosin-containing protein (VCP or p97)

Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism

Oxindole derivatives as inhibitors of TAK1 kinase

The Locus Control Region Is Necessary for Gene Expression in the Human β-Globin Locus but Not the Maintenance of an Open Chromatin Structure in Erythroid Cells

Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis

Matching-adjusted Indirect Comparison of Current Treatments for NMOSD and Evaluation of Long-term Effectiveness (P10-14.006)

Safety and Efficacy of Inebilizumab in AQP4+ NMOSD Participants with History of Immunosuppression Treatment Prior to N-MOmentum Study (P13-5.003)

Genomic Targeting of Methylated DNA: Influence of Methylation on Transcription, Replication, Chromatin Structure, and Histone Acetylation

Long-term Comparative Efficacy of Inebilizumab in the AQP4+ Subpopulation from N-MOmentum Open-label Period Versus Azathioprine and Immunosuppressants and Versus Placebo in Patients with NMOSD (S32.001)

Pharmacodynamic modeling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders (1872)

Replication Initiation Patterns in the β-Globin Loci of Totipotent and Differentiated Murine Cells: Evidence for Multiple Initiation Regions

Pharmacodynamic modelling and exposure–response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders

WED-152 Design and study population of MITIGATE: the first multinational randomized controlled clinical trial in IgG4 related disease, evaluating the efficacy and safety of the CD19 B cell depleting agent inebilizumab

Long-Distance Control of Origin Choice and Replication Timing in the Human β-Globin Locus Are Independent of the Locus Control Region

Suchergebnisse filtern